Carl Zeiss Meditec : Weak market environment triggers a harsh warning
>Top line suffers from weaker market environment in various areas - On the back of the weaker-than-expected underlying development, Carl Zeiss Meditech has reduced its FY 2024 guidance to revenues of around € 2bn (from € 2.1-€2.15bn before). The acquired DORC will add € 100m to this number. Our forecast stood at € 2.28bn, consensus € 2.29bn both including c. € 100m related to the DORC acquisition. Reasons for the slower development are more cautious expectations for c...Carl Zeiss Meditec is a holding company. Co.'s businesses are focused on two primary areas: Ophthalmology and Microsurgery. In Ophthalmology, Co.'s operations are divided in to two strategic business units: Ophthalmic Systems, which includes a range of laser and diagnostic systems for ophthalmology; and Surgical Ophthalmology, which consists of activities in the field of ophthalmic implants and consumables. In Microsurgery, Co. provides surgical microscopes and visualization solutions, e. g. for ear, nose and throat surgery, or neurosurgery. These products are mainly used to assist with the removal of tumors, as well as the treatment of vascular diseases and functional disorders.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.